India Post News Paper

Blog

 Breaking News

AstraZeneca’s vaccine less protective against virus variant in South Africa

AstraZeneca’s vaccine less protective against virus variant in South Africa
February 08
10:51 2021

CAPE TOWN: South Africa is pausing the country’s rollout of Oxford/AstraZeneca COVID-19 vaccine after a study showed it offered reduced protection from the COVID-19 variant first identified there, CNN reported citing South African health officials on Sunday (local time).

According to South Africa Minister of Health Dr Zweli Mkhize, the hold of vaccine would be temporary while scientists figure out how to most effectively deploy the AstraZeneca vaccine.
South Africa will move forward with the deployment of vaccines made by Pfizer/BioNTech and Johnson and Johnson, Mkhize said.

Early data released showed that two doses of the Oxford/AstraZeneca Covid-19 vaccine provided only “minimal protection” against mild and moderate Covid-19 from the variant first identified in South Africa, CNN reported.

In the AstraZeneca-Oxford trial in South Africa, about 2,000 participants were given either two doses of the vaccine or placebo shots, according to the study, which has not been released.

Researchers said that viral neutralization against the B.1.351 variant was “substantially reduced” when compared to the earlier coronavirus strain.The vaccine’s efficacy against severe Covid-19, hospitalization and death were not assessed.

The company is “working closely with the South African Ministry of Health on how best to support the evaluation against the severe disease of the B.1.351 variant, and start to bring this vaccine to the South African people should it prove to be successful,” CNN quoted AstraZeneca spokesperson’s statement.

The statement said the company believes its vaccine will still protect against severe disease from the new B.1.351 variant, particularly when the dosing interval is eight to 12 weeks. However, in a previous statement, the company said it is working with Oxford University to adapt the vaccine against the B.1.351 variant so “it is ready for Autumn delivery should it be needed.”

World Health Organization’s independent vaccine panel will meet Monday (local time) to discuss the AstraZeneca vaccine and what the new study means for vaccines going forward, said Maria Van Kerkhove, WHO’s technical lead for COVID-19.

“Some preliminary studies suggesting reduced efficacy. But again, those studies aren’t fully published yet,” CNN quoted Van Kerkhove as saying. She added that it’s critical to have more than one safe and effective vaccine: “We cannot rely on only one product.” According to The New York Times, AstraZeneca’s vaccine has been authorised by around 50 countries, including Britain, which has found dozens of cases of the variant first seen in South Africa. (ANI) 

Comments

comments

About Author

India Post Newspaper

India Post Newspaper

Refresh yourself every morning with India Post news coverage, videos & photos in India Post News Paper. Check out the news stories from India and the World.

Related Articles

EPAPER – LATEST EDITION – May 20th, 2022

ADVERTISEMENT – ZEE5

ZEE 5 Subscription in USA

ADVERTISEMENT – CALTRANS

Caltrans Near Me

ADVERTISEMENT – ACVOTE.ORG

ACVOTE

ADVERTISEMENT – SMCVOTE

SMCVOTE

ADVERTISEMENT – SKYRIVER CASINO

Skyriver

ADVERTISEMENT – 22BET

22Bet Casino

POPULAR CATEGORIES

50 SPIRITUAL APPETIZERS – VINOD DHAWAN

50-ad-Indiapost

It’s a lovely book. It feels energetically clear and light. It’s easy to read, dip in and out and most importantly it offers information without fluff! Blessings on this project.

Jac O’Keeffe
Spirituality teacher based in USA.

*Available on Amazon, Flipkart & other online stores*

Download Media Kit

India Post Media Kit